ArTara Therapeutics, Inc. (TARA)
| Market Cap | 100.83M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -37.38M |
| Shares Out | 11.23M |
| EPS (ttm) | -4.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $8.79 |
| Previous Close | $9.03 |
| Change ($) | -0.24 |
| Change (%) | -2.66% |
| Day's Open | 8.98 |
| Day's Range | 8.75 - 9.04 |
| Day's Volume | 114,256 |
| 52-Week Range | 8.72 - 67.08 |
- On Track to File IND and Initiate Phase 1 Trial of TARA-002 in Patients with NMIBC by Year-End -
Novavax, Inc. (NASDAQ: NVAX), Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Protara Therapeutics, Inc. (NASDAQ: TARA) are among the biotech movers Friday. Novavax Moves On Mid-stage Malaria Vaccine Dat...
Company to conduct additional clinical study to support submission of a Biologics License Application for TARA-002 in Lymphatic Malformations Company to conduct additional clinical study to support subm...
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with si...
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with si...
- Initiation of Phase 1 Trial of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer on Track to Commence by Year-End -
NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has reassesse...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
- On T rack to Complete GMP Batch Runs in Mid-2021 to C onfirm C omparability B etween TARA-002 and OK-432 - - Expect to I nitiate Phase 1 T rial for TARA-002 in P atients with N on- M uscle I nvasive B...
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases with sig...
NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with ...
NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with ...
- Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs -
About TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed ... [Read more...]
| Industry Biotechnology | |
| CEO Jesse Shefferman | Employees 27 |
| Stock Exchange NASDAQ | Ticker Symbol TARA |
Analyst Forecasts
According to 3 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price forecast is 41.50, which is an increase of 372.13% from the latest price.